Nefrología Vol. 32 Nº 1 Año 2012
Nefrologia (Madr.) 2012;32:73-8 | doi: 10.3265/Nefrologia.pre2011.Jul.10916

Densidad mineral y metabolismo óseo en pacientes en hemodiálisis. Correlación con la hormona paratifoidea, el 25(OH)D3 y la leptina

Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin


a Second Division of Endocrinology, Alexandra Hospital, Athens, Greece,
b Renal Unit, Alexandra Hospital, Athens, Greece,
Resumen
Abstract
Palabras Clave:
Ver / Descargar PDF
Referencias Bibliográficas
1.
Hruska KA, Teitelbaum SL. Mechanisms of disease: renal osteodystrophy. N Engl J Med 1995;333(3):166-74. [Pubmed]
2.
Yamamoto N. Morphological analysis of bone dynamics and metabolic bone disease. Bone Histomorphometry in CKD-MBD (chronic kidney disease mineral bone disorder). Clin Calcium 2011;21(4):589-92. [Pubmed]
3.
De Vernejoul MC, Kuntz D, Miravet L, Gueris J, Bielakoff J, Ryckewaert A. Bone  histomorphometry in hemodialysed patients. Metab Bone Dis Rel Res 1981;3:175-9. 
4.
Yamamoto N.  Morphological analysis of bone dynamics and metabolic bone disease. Bone  Histomorphometry:  the basic methods and role of bone research and clinical significance. Clin Calcium 2011;21(4):529-33.
5.
Sherrard D, Hercz G, Pei Y. The spectrum of bone disease in end stage renal failure-an evolving disorder. Kidney Int 1993;43(2):436-42. [Pubmed]
6.
Taal M, Masud T, Green D, Cassidy M. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999;14:1922-8.  [Pubmed]
7.
Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33(2):287-93.  [Pubmed]
8.
Urena P, De Vernejoul MC. Circulating markers of bone remodeling in uremic patients. Kidney Int 1999;55:2141-56.  [Pubmed]
9.
Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser¿s zones independent of calcitriol? Kidney Int 1999;55(6):2169-77.
10.
Thomas T, Gori F, Khosla S. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140(4):1630-8. 
11.
Holloway WR, Collier FM, Aitken CJ. Leptin inhibits osteoclast generation. J Bone Miner Res 2002;17:200-9.  [Pubmed]
12.
Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and supresses renal 1alpha 25-dihydroxyvitamin D3 synthesis in leptin deficient mice. J Bone Miner Res 2010;25(8):1711-23. [Pubmed]
13.
Steppan CM, Crawford DT, Chidsey-Fink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92(1-3):73-8.  [Pubmed]
14.
Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central role of bone mass. Cell 2000;100(2):197-207. [Pubmed]
15.
Song J, Li H, Zhang XD. Influence of diferent bpood purification treatment on the serum leptin and neuropeptide Y levels in patients with chronic renal failure. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010;26(11):1116-8. [Pubmed]
16.
Taskapan MC, Taskapan H, Sahin I, Keskin L, Atmaca H, Ozyalin F. Serum leptin, resistin and lipid levels in patients with end stage renal failure with regard to dialysis modality. Ren Fail 2007;29(2):147-54. [Pubmed]
17.
Mantzoros CS. Leptin in renal failure. J Ren Nutr 1999;9(3):122-5.  [Pubmed]
18.
 Mallamaci F, Tripepi G, Zoccali C. Leptin in end stage renal disease (ESRD): a link between fat mass, bone and the cardiovascular system. J Nephrol 2005;18(4):464-8. Review. [Pubmed]
19.
19. Ghazali A, Grados F, Oprisiu R, Bunea D, Moriniere P, El Esper N, et al. Bone mineral density directly correlates with elevated serum leptin in haemodialysis patients. Nephrol Dial Transplant 2003;18:1882-90. [Pubmed]
20.
Zayour D, Daouk M, Medawar W, Salamoun M, El-Hajj Fuleihan G. Predictors of bone mineral density in patients on hemodialysis. Transplant Proc 2004;36(5):1297-301. [Pubmed]
21.
Urena P, Bernard-Poenaru O, Ostertag A. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003;18:2325-31.  [Pubmed]
22.
Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Stathakis CP, Diamanti-Kandarakis E, et al. Associations between osteoprotegerin and femoral neck BMD in haemodialysis patients. J Bone Miner Metab 2008;26(1):66-72. Epub 2008 Jan 10. [Pubmed]
23.
Negri A, Álvarez-Quiroga M, Bravo M, Fradinger E, Jacob de Marino A. Estimation of the prevalence of low turnover renal osteodystrophy using biochemical markers in a peritoneal dialysis population. Nefrologia 2001;21(4):392-4.  [Pubmed]
24.
Fontaine M, Albert A, Dubois R, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000;54:218-26.  [Pubmed]
25.
Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 1996;19:549-55.  [Pubmed]
26.
Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996;28:515-22. [Pubmed]
27.
Montagnani A, Gonnelli S, Cepollaro C, Mangeri M, Martini S, Franci MB, et al. A new serum assay to measure N-terminal fragment of telopeptide of type 1 collagen in patients with renal osteodystrophy. Eur J Intern Med 2003;14:172-7. 
28.
Nakashima A, Yorioka N, Mizutani T, Yamagata Z, Ueno T, Takasugi N. Serum cross-linked N-terminal telopeptide of type 1 collagen for evaluation of renal osteodystrophy in hemodialysis patients. Nephron Clin Pract 2005;99:c78-c85.  [Pubmed]
29.
Van der Wielen RP, Lowik MR, Van den Berg H, De Groot L, Haller J. Serum vitamin D concentrations in elderly in Europe. Lancet 1995;346:207-10.  [Pubmed]
30.
Thomas MK, Lloyd Jones DM, Thadam AJ, Shaw AC, Fikelstein R. Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-83.  [Pubmed]
31.
Bayard F, Bey P, Ton That M, Louvet J. Plasma 25OH cholecalciferol in chronic renal failure. Eur J Clin Invest 1973;3:447-50.  [Pubmed]
32.
Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MG. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 2001;86(5):1884-7.  [Pubmed]
33.
Yamauchi M, Sugimoto T, Yamaguchi T, Naganuma S, Akiyama Y, Nuki Y, et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in post-menopausal women. Clin Endocrinol (Oxf) 2001;55(3):341-7.
34.
 34. Blain H, Vuillemin A, Guillemin F, Durant R, Hanesse B, De Talance N, et al. Serum leptin levels is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2002;879(3):1030-5.  
35.
Rauch F, Blum WF, Klein K, Allolio B, Schonau E. Does leptin have an effect on bone in adult women? Calcif Tissue Int 1998;63:453-5.   [Pubmed]
36.
Odabasi E, Ozata M, Turan M, Bingol N, Yonem A, Cakir B, et al. Plasma leptin concentrations in post menopausal women with osteoporosis. Eur J Endocrinol 2000;142(2):170-3.  [Pubmed]
37.
Thomas T, Burguera B, Melton LJ 3rd, Atkinson EJ, O¿Fallon WM, Riggs BL, Khosla S. Role of serum leptin, insulin and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001;29(2):114-20. [Pubmed]
Órgano Oficial de la Sociedad Española de Nefrología
Contactar | Web Map | Aviso legal